<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Metx — News on 6ix</title>
<link>https://6ix.com/company/metx</link>
<description>Latest news and press releases for Metx on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 30 Jan 2026 14:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/metx" rel="self" type="application/rss+xml" />
<item>
<title>ME Therapeutics Scientific and Corporate Update</title>
<link>https://6ix.com/company/metx/news/therapeutics-scientific-corporate-140000864</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-scientific-corporate-140000864</guid>
<pubDate>Fri, 30 Jan 2026 14:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, January 30, 2026--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company working on novel cancer fighting drugs that reprogram and redirect immune cells to fight cancer, is pleased to provide a corporate update and an outline of its strategic positioning within the rapidly emerging in vivo immune cell engineering and chimeric antigen receptor (CAR) space.</description>
</item>
<item>
<title>ME Therapeutics Granted Licence for CD22 Nanobody Asset to Expand Next-Gen In Vivo CAR Cell Therapy Program</title>
<link>https://6ix.com/company/metx/news/therapeutics-granted-licence-cd22-nanobody-130000586</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-granted-licence-cd22-nanobody-130000586</guid>
<pubDate>Thu, 16 Oct 2025 13:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, October 16, 2025--ME Therapeutics has entered into a technology license agreement with the National Research Council of Canada to license a nanobody-based CD22 binder.</description>
</item>
<item>
<title>ME Therapeutics Added to CSE25 Index</title>
<link>https://6ix.com/company/metx/news/therapeutics-added-cse25-index-130000426</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-added-cse25-index-130000426</guid>
<pubDate>Fri, 10 Oct 2025 13:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, October 10, 2025--ME Therapeutics Holdings Inc. announced today it has been added to the CSE25 Index, a signature benchmark of the Canadian Securities Exchange.</description>
</item>
<item>
<title>ME Therapeutics Secures U.S. Patent for Lead Candidate and Advances Broader Therapeutic Programs</title>
<link>https://6ix.com/company/metx/news/therapeutics-secures-u-patent-lead-130000462</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-secures-u-patent-lead-130000462</guid>
<pubDate>Fri, 26 Sep 2025 13:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, September 26, 2025--ME Therapeutics secures U.S. patent for lead candidate and advances broader therapeutic programs.</description>
</item>
<item>
<title>ME Therapeutics Receives Support to Advance mRNA Therapeutic Candidates for Cancer and Inflammatory Disease</title>
<link>https://6ix.com/company/metx/news/therapeutics-receives-support-advance-mrna-100000369</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-receives-support-advance-mrna-100000369</guid>
<pubDate>Wed, 21 May 2025 10:00:00 GMT</pubDate>
<description>VANCOUVER, British Columbia, May 21, 2025--ME Therapeutics Holdings Inc. ("ME Therapeutics" or the "Company") (CSE: METX) (FSE: Q9T), a publicly listed preclinical biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, today announced that its subsidiary, ME Therapeutics Inc., is receiving advisory services and up to $140,000 in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). The project will support t</description>
</item>
<item>
<title>ME Therapeutics Announces It Has Engaged Lucosky Brookman LLP to Explore a Listing on the NASDAQ or NYSE</title>
<link>https://6ix.com/company/metx/news/therapeutics-announces-engaged-lucosky-brookman-140000248</link>
<guid isPermaLink="true">https://6ix.com/company/metx/news/therapeutics-announces-engaged-lucosky-brookman-140000248</guid>
<pubDate>Mon, 03 Mar 2025 14:00:00 GMT</pubDate>
<description>Vancouver, British Columbia--(Newsfile Corp. - March 3, 2025) - ME Therapeutics Holdings Inc. (CSE: METX) (FSE: Q9T) ("ME Therapeutics" or the "Company"), a preclinical stage biotechnology company working on novel cancer fighting drugs in the field of immuno-oncology, is pleased to announced that it has retained Lucosky Brookman LLP, a distinguished corporate finance and securities law firm, to assist in evaluating an uplisting to a senior national securities exchange such as the Nasdaq Capital</description>
</item>
</channel>
</rss>